Total Serum Bilirubin Levels at or Above the ETT Wu YW Kuzniewicz MW Wickremasinghe AC et al Risk of cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold a populationbased study ID: 788981
Download The PPT/PDF document "JAMA Pediatrics Journal Club Slides:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
JAMA Pediatrics Journal Club Slides:Total Serum Bilirubin Levels at orAbove the ETT
Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al.
Risk of cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study
.
JAMA Pediatr
.
Published online January 5, 2015. doi
:10.1001/jamapediatrics.2014.3036.
Slide2BackgroundExchange transfusion is recommended for newborns with total serum bilirubin (TSB) levels thought to place them at risk for
cerebral palsy (CP
).The excess risk of CP among these infants is unknown.Study ObjectiveTo quantify the risks of CP and CP consistent with kernicterus that are associated with high TSB levels based on the 2004 American Academy of Pediatrics exchange transfusion threshold (ETT) guidelines.
Introduction
Slide3Study Design
Double-cohort study
nested within the Late Impact of Getting Hyperbilirubinemia or Phototherapy (LIGHT) birth cohort.SettingKaiser Permanente Northern California.PatientsTwo cohorts sampled from a population of all 525 409 infants born at ≥5 weeks’ gestation at Kaiser Permanente Northern California from January 1,
1995, through December 31, 2011.
Exposed cohort: All 1833 infants with ≥1 TSB measurement at or above the ETT based on age at testing, gestational age, and results of direct antiglobulin testing.Unexposed cohort: 20% random sample of infants with all TSB levels below the ETT.
Methods
Slide4Methods
Outcomes
CP: nonprogressive congenital motor dysfunction with hypertonia or dyskinesia (choreoathetosis or dystonia) CP consistent with kernicterus: bilateral globus pallidus injury in the setting of dyskinetic CP.Limitations Measured maximum TSB levels are only estimates of
true
peak levels.CP diagnosis relied on clinical records (ie, patients not examined for study).Brain magnetic resonance imaging performed at different ages without a standard protocol.Absolute risk differences for extreme levels of hyperbilirubinemia were calculated based on small numbers of exposed
infants,
thus generating wide confidence
intervals
.
Slide5Results1833 of 525 409
infants
(0.3%) were exposed to ≥1 TSB level at or above the ETT.Exposed infants were more likely to be male, Asian, and preterm. CP diagnosed in 7 of 1833 infants (0.4%) exposed to a TSB level at or above the ETT compared with 86 of 104 716 unexposed infants (0.1%) (relative risk,
4.7 [95
% CI, 2.2-10.0]; P < .001).Risk of CP was highest for infants with most severe elevations of TSB levels.No difference between the degree of elevation in TSB levels above the ETT and
the peak
TSB
levels
in ability to predict hypertonic/dystonic
CP (areas under the receiver operating characteristic curve, 0.71 vs 0.70;
P
= .79).
Slide6Selection of Infants With CP Within the 2 Study Cohorts
Results
Slide7Results
Characteristics of Infants With and Without a TSB Level Above the EET
Slide8Results
Risk for CP Associated With Varying Elevated TSB Levels
Slide9Results7 infants had CP and
a
TSB Level Above the ETT3 had CP consistent with kernicterus (ie, T2 hyperintensity in bilateral globus pallidus, and dyskinetic CP).4 had other causes of CP.
Incidence of CP consistent with kernicterus
was 0.57 per 100 000 births.All 3 infants with CP consistent with kernicterus had both of the following:TSB level >5 mg/dL above the ETT.≥2 risk factors for neurotoxicity (ie, prematurity,
glucose-6-phosphate dehydrogenase [G6PD]
deficiency, hypoalbuminemia,
hypoxia-
ischemia,
and/or
sepsis).
Slide10Results
Clinical Characteristics of 7 Infants With CP Who Were Exposed to a TSB Level Above the ETT
Slide11CommentThe 2004
American Academy of Pediatrics ETT
guidelines effectively identified all cases of CP consistent with kernicterus in a large population. Incidence of CP due to kernicterus in United States:Study’s estimate (0.57 per 100 000 births) falls within the range
of previously reported estimates (
0.4-2.7 per 100 000 births).All 3 patients with CP consistent with kernicterus had peak TSB levels >5 mg/dL above the ETT as well as ≥2 neurotoxicity risk factors.Although maximum TSB levels up to 5 mg/dL above the ETT were almost always benign, infants with such levels
should
not
be excluded from treatment. Infants
with maximum TSB levels up to 5 mg/dL above the ETT
may have good outcomes
precisely because they were treated and their TSB levels were prevented from
increasing.
Slide12CommentCP consistent with kernicterus was rare in this modern cohort of term and late preterm
infants and
did not occur in a single infant with hyperbilirubinemia who was otherwise healthy with no neurotoxicity risk factors present, regardless of the severity of elevation of the TSB level.Findings support the suggestion that infants with hyperbilirubinemia without neurotoxicity risk factors may have a higher tolerance than recognized in current management guidelines.These data, along with estimates of risks and costs of treatment, should be considered when developing future updated guidelines for management of jaundice in term and late preterm newborns.
Slide13If you have questions, please contact the corresponding author:Yvonne
W. Wu
, MD, MPH, Department of Neurology, University of California, San Francisco, 675 Nelson Rising Ln, Ste 411, San Francisco, CA 94158 (wuy@ucsf.edu).Funding/SupportThis study was supported by
grant
R01HS020618 from the Agency for Healthcare Research and Quality.Conflict of Interest DisclosuresDrs Wu and Newman have provided expert consultation on cases related to CP and/or kernicterus. No other disclosures were reported.
Contact Information